Form 4: Tonix Pharmaceuticals Director Stillwell Receives Stock Option Grant

Director Richard Newcomb Stillwell received a stock option grant for 10,000 shares of Tonix Pharmaceuticals Holding Corp. on May 13, 2025.

Summary

• Richard Newcomb Stillwell, a director of Tonix Pharmaceuticals Holding Corp., was granted a stock option for 10,000 shares on May 13, 2025.
• The option has an exercise price of $20.18.
• The option vests on the earlier of the one-year anniversary of the grant date (May 13, 2026) or the Issuer's 2026 Annual Meeting of Stockholders and expires on May 13, 2035.
• Following the transaction, Stillwell directly owns 10,000 shares of Tonix Pharmaceuticals Holding Corp.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a stock option grant, which is a neutral event. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the pharmaceutical industry, to align their interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in ways that increase shareholder value.

Key Dates

Keywords

Stock Option, Form 4, Director, TNXP, Tonix Pharmaceuticals, Beneficial Ownership